Objectives: Despite the increasing incidence of carbapenem-intermediate or -resistant Enterobacteriaceae (CIRE), risk factors associated with CIRE infections have not been well defined. This study characterizes factors associated with CIRE among two different source populations.
Introduction
Carbapenem antibiotics have traditionally been a mainstay in therapy against infections caused by Gram-negative bacteria, particularly those caused by organisms with reduced susceptibility to other antimicrobials. However, effective use of carbapenem antibiotics in clinical practice has been compromised by the emergence of antibiotic resistance. 1, 2 Most recently, resistance to carbapenems has been reported among Enterobacteriaceae, a family of organisms typically pan-susceptible to carbapenems. The first reported outbreak of carbapenem-resistant Klebsiella pneumoniae and Enterobacter spp. was in Brooklyn, NY, USA, in 2003. Ribotyping confirmed the presence of the bla KPC gene, encoding a molecular Ambler class A b-lactamase that confers resistance to carbapenems. 3 -6 Since this initial report, the incidence of carbapenem-intermediate or -resistant Enterobacteriaceae (CIRE) infections has steadily risen in healthcare settings throughout the world. 7 -9 Despite the increasing incidence of CIRE, risk factors associated with CIRE have not been well defined. 10 -13 The intent of this study was to characterize factors associated with CIRE. When describing risk factors for CIRE infections, two clinically important questions merit attention. 14, 15 First, it is important to identify predictors of CIRE among patients with suspected Enterobacteriaceae infections for empirical therapy selection. Given the importance of early, appropriate therapy, an understanding of patients at greatest risk for CIRE among patients with suspected Enterobacteriaceae infections is critical when selecting an empirical antibiotic regimen. 16 Second, one must determine what clinical factors give rise to CIRE among the general hospitalized population. An appreciation of these factors is necessary when devising strategies to mitigate the risk of developing a CIRE infection.
Methods

Study population and design
A case-control study was performed at the Albany Medical Center Hospital (AMCH), Albany, NY, USA, between January 2005 and December 2009. Cases were adults (age ≥18 years) with a cultureconfirmed Enterobacteriaceae infection 17 with reduced susceptibility (intermediate or resistant) to carbapenems. 18 The CIRE cases were matched 1:1 to patients from two different control series. The first control group consisted of patients with carbapenem-susceptible Enterobacteriaceae (CSE) infections. The second control group consisted of hospitalized patients admitted to AMCH for ≥72 h within 30 days of the CIRE case culture date.
The research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. The study was approved by both the AMCH and Albany College of Pharmacy and Health Sciences institutional review boards (expedited approvals).
CSE control group selection
The CSE control group consisted of adult (age ≥18 years) patients admitted to AMCH with a culture-confirmed CSE infection recorded during their hospitalization. A calliper-based sampling strategy was used to select a CSE control for each CIRE case. Matching criteria (1:1) for control selection were: (i) organism (K. pneumoniae, Enterobacter aerogenes, Enterobacter cloacae or Citrobacter freundii); (ii) date of culture (+30 days of CIRE culture date); (iii) specimen type (abdominal, blood, respiratory, urine or wound/tissue/graft); (iv) hospital ward at culture collection; and (v) pre-culture length of stay (LOS; ,72 or ≥72 h). If no CSE patients could be identified on the same hospital ward, the search was expanded to identify CSE controls from adjacent hospital wards of a similar nature [intensive care unit (ICU) versus non-ICU]. In the event where multiple matches were identified, the match with the culture date closest to that of the case patient was selected.
Hospitalized control group selection
The analyses comparing CIRE cases with hospitalized controls were restricted to cases with a CIRE culture collection date ≥72 h after admission. Cases with a CIRE initial culture collection date within 72 h of administration were not included because a fully enumerable and identifiable source population that would have given rise to these CIRE cases could not be readily ascertained. Hospitalized controls were matched in a 1:1 ratio to a CIRE case by hospital ward and culture date. In particular, for each CIRE case, all adult (age ≥18 years) patients residing in the same hospital ward within 30 days of the culture date of the CIRE case were identified. A random number generator (www.random.org) was used to select a control patient for each CIRE case with a total hospital LOS of at least 72 h.
Data collection
Clinical covariates
Data were extracted from the patients' medical records by a trained reviewer using a structured data collection instrument. Information collected from patients' medical records included the following: demographics; medical history and co-morbid conditions; residence in a healthcare institution for ≥72 h within 180 days of hospital admission; location prior to admission; ward of admission; hospital course (duration and ward location); receipt of mechanical ventilation, urinary catheterization or surgery prior to culture date (CIRE cases and CSE controls) or during hospitalization (hospitalized controls); antibiotic exposure history; and source of infection (blood, urinary tract, tissue/wound/graft, abdominal source, respiratory or other).
Collected demographic information included age, sex and weight. Recorded co-morbidities included diabetes mellitus, heart failure, 19 chronic obstructive pulmonary disease, renal failure (defined by the need for renal replacement therapy), alcoholism or substance abuse, HIV infection, presence of decubitus ulcers, active cancer or malignancy, and immunosuppression (defined by haematopoietic stem cell transplant, receipt of corticosteroids .14 days at an equivalent dose of 20 mg of prednisone or asplenia). Both the individual and cumulative number of co-morbid conditions were tabulated. The cumulative number of prior co-morbid conditions was categorized as 0, 1, 2 or ≥3.
The severity of illness at the time of culture was recorded by two measures: the Acute Physiological and Chronic Health Evaluation II (APACHE-II) score 20, 21 and the Chronic Disease Score-Infectious Diseases (CDS-ID). 22 The APACHE-II score was calculated using the patient's worst physiological score within the first 24 h of culture collection for CIRE cases and CSE controls. For hospitalized controls, the APACHE-II score was computed at the median date of hospitalization. 21 The CDS-ID was calculated at the time of admission.
All antibiotics administered for ≥24 h during the current hospitalization were recorded. The information collected included the drug name, start date/time, dose, route of administration, dosing frequency, stop date/time and total duration of use. Only antibiotic exposures that occurred prior to the culture date were considered for CIRE cases and CSE controls. For hospitalized controls, all antibiotic exposures that occurred during the hospital stay were tabulated. Both individual and cumulative antibiotic exposures were tabulated. For the purpose of the analysis, the number of prior antibiotic exposures was consolidated into an ordinal variable with the following four rank-ordered categories; 0, 1, 2 and ≥3 prior antibiotic exposures.
Microbiology
All microbiology cultures for the patients' hospitalization were documented. Carbapenem susceptibility was defined by disc diffusion using the 2010 CLSI interpretative criteria for carbapenems and Enterobacteriaceae. 18 Isolates with an ertapenem or meropenem zone size of ≤22 mm were considered to be 'intermediate' or 'resistant' and were classified as a CIRE and were eligible to serve as a case if other inclusion criteria were met. Isolates with both ertapenem and meropenem zone sizes ≥23 mm were considered susceptible and these patients were eligible to serve as CSE controls if the other inclusion criteria were satisfied.
Isolates from CIRE case patients were sent to the New York State Department of Health Wadsworth Center Laboratory, Albany, NY, USA, for determination of the bla KPC gene by PCR. 23 
Statistical analyses
Two sets of analyses were performed to address each of the study aims. The first set of analyses sought to identify the predictors of CIRE among patients with Enterobacteriaceae infections by comparing exposure odds between CIRE cases and CSE controls. The second set of analyses focused on delineating factors associated with CIRE among hospitalized patients by comparing exposure odds between CIRE cases and hospitalized controls.
For the first set of analyses, bivariate analyses between cases and controls were performed using McNemar's test or the Wilcoxon matchedpairs test for categorical exposure variables and the paired t-test or Wilcoxon-Mann-Whitney test for continuous exposure variables. For variables where the expected cell frequency was less than 5, the exact binomial distribution was utilized. Significant breakpoints in continuous variables were sought with classification and regression tree (CART) 24 CART is an analytic tool that identifies cut-points in continuous variables, maximizing the difference in outcomes between 'exposure' groups based on the goodness of split statistic. 24 In essence, it creates a categorical exposure variable from a continuous variable where the difference in outcomes between the resultant categorical exposure groups is maximized. Conditional logistic multivariable regression was performed to determine variables independently associated with CIRE. All variables that varied between cases and controls at a P value ,0.2 in the bivariate analyses and was present in .5% of the study population were included at model entry. A stepwise approach was used to derive a parsimonious model, and variables remained in the final model if their associated P value was ,0.05. Interaction terms were explored among the variables in the final model. If the interaction terms were significantly associated with CIRE, they were retained in the model. To determine if the final odds ratios (ORs) were confounded, all potential confounders were put back into the model for assessment. If the potential confounder did not change the measure of association ≥10%, it was not retained in the model. A series of stratified and restricted conditional logistic regression analyses were also performed to determine if clinical covariates predictive of CIRE varied by infecting organism (Klebsiella spp. versus non-Klebsiella spp.) or the presence of the bla KPC gene.
Bivariate analyses for the second set of analyses between cases and hospitalized controls were performed using the Pearson x 2 or Fisher's exact test for categorical exposure variables and Student's t-test or Mann-Whitney U-test for continuous exposure variables. Significant breakpoints in continuous variables were also sought with CART. To identify variables independently associated with CIRE, a series of unconditional multivariable logistic regression analyses were performed similar to the methods described above. All calculations were computed using SAS version 9.0 (SAS, Cary, NC, USA), SPSS version 11.5 (SPSS, Chicago, IL, USA) and CART software (Salford Systems, San Diego, CA, USA).
Results
CIRE cases
During the study period, 102 patients met the CIRE case definition (Table 1) . Of the 102 CIRE cases, 100 (98%) were resistant to ertapenem and 2 (2%) were intermediate. Meropenem intermediate susceptibility and resistance were observed in 7 (6.9%) and 76 (74.5%) of the CIRE cases, respectively. Seventy-three cases (71.6%) were bla KPC positive.
The average (SD) age was 58.5 (17.5) years and the majority of patients had ≥1 co-morbid conditions. The distribution of pathogens among CIRE cases was as follows: K. pneumoniae (54.9%); E. cloacae (40.2%); E. aerogenes (3.9%); and C. freundii (1.0%). The most common sites of infection were the urinary tract (40.2%) and respiratory tract (24.5%). The median [interquartile range (IQR)] hospital stay prior to CIRE culture collection was 13 (4-23) days and .60% of CIRE cases had ≥1 antibiotic exposure prior to culture collection.
Covariates predictive of CIRE among patients with Enterobacteriaceae infections
Comparisons of clinical covariates between CIRE cases and CSE controls are displayed in Table 1 . Compared with CSE controls, CIRE cases were younger and had more co-morbid conditions, a higher average APACHE-II score, a longer median hospital stay prior to culture collection and more prior antibiotic exposures. When examining the specific antibiotic classes, use of b-lactams, penicillin-class antibiotics, cephalosporins, carbapenems and fluoroquinolones prior to culture was significantly higher among patients with CIRE than CSE controls. Among the cephalosporins, the use of fourthgeneration cephalosporins was more frequent among CIRE cases than CSE controls. Among the carbapenems, the use of meropenem prior to culture was more frequent among CIRE cases than CSE controls. Only one patient (a CIRE case) received ertapenem prior to culture. To further quantify these relationships, CART was utilized to identify the number of days of antimicrobial therapy prior to culture associated with an increased risk of CIRE. In the CART analyses, the following were significantly associated with CIRE: prior b-lactam exposure ≥10 days; prior penicillin-class antibiotics exposure ≥13 days; and prior fluoroquinolone exposure ≥4 days.
Results of the multivariate logistic regression analyses are provided in Table 2 . In the overall model, all variables associated with CIRE in the bivariate analysis at a P value ,0.2 and present in .5% of study population (male, age, weight, dialysis, decubitus ulcers, number of co-morbidities, LOS prior to culture, urinary catheter, APACHE-II score, CDS-ID, prior b-lactam exposure, prior penicillin-class antibiotics, prior cephalosporin exposure, prior carbapenems, prior fluoroquinolone exposure, prior fluoroquinolone ≥4 days, prior b-lactam ≥10 days and number of prior antibiotic exposures) were included at model entry and the only variable associated with CIRE among patients with Enterobacteriaceae infections was the number of prior antibiotic exposures. The cumulative number of antibiotic exposures was modelled as a rank-ordered ordinal variable, such that the OR was representative of a one-unit increase in the number of prior antibiotic exposures. To determine if the final ORs for the number of cumulative antibiotic exposures were confounded, all variables associated with CIRE in the bivariate analysis at a P value ,0.2 and present in .5% of population were put back into the model. None of the variables changed the final OR for the number of cumulative antibiotic exposures by ≥10%.
Several other models were evaluated that excluded the cumulative number of prior antibiotic exposures. These models included the variables associated with CIRE in the bivariate analysis at a P value ,0.2 and various combinations of individual antibiotic exposure variables (CART-defined exposures, class exposures, specific agent exposures etc.). For each of these models, the only independent variables were some combination of the individual prior antibiotic exposures included at model entry. However, the model with the cumulative number of antibiotic exposures had the lowest 22 log-likelihood out of all of the models evaluated.
Results of the logistic analyses that were restricted by infecting organism (Klebsiella spp. versus non-Klebsiella spp.) and presence of the bla KPC gene were identical to the overall logistic regression analysis ( Table 2) . As a final measure, effect measure modification between the number of cumulative antibiotic exposures and clinical covariates was assessed through the use of interaction terms in all the multivariable conditional logistic regression analyses (overall and restricted) performed. There were no significant departures from multiplicativity (no effect modification) in any of the models evaluated.
Factors associated with CIRE among hospitalized patients
Among the CIRE cases, 85 patients had a hospital LOS ≥72 h. Comparison of the clinical characteristics between the 85 CIRE Patel et al. Table 3 . The proportion of patients with diabetes, heart failure and receipt of haemodialysis was higher among CIRE cases relative to hospitalized controls. Receipt of care in the ICU, mechanical ventilation prior to culture and number of prior antibiotic exposures were also more frequent among CIRE cases compared with hospitalized controls. Individual prior antibiotic exposures associated with CIRE were fluoroquinolones, b-lactam antibiotics, penicillinclass antibiotics and carbapenems. Similar to the analysis of the CSE controls, use of meropenem prior to culture was more frequent among CIRE cases than hospitalized controls. Only one patient (a CIRE case) was administered ertapenem prior to culture. Prior fluoroquinolone ≥5 days, prior b-lactam ≥10 days and prior penicillins ≥8 days were the only antibiotics where CART-derived breakpoints could be identified and significantly associated with CIRE. The results of the multivariable logistic regression model are displayed in Table 2 . Similar to the CIRE case versus CSE control logistic regression analyses, all variables associated with CIRE in the bivariate analysis at a P value ,0.2 and present in .5% of study population [diabetes, heart failure, dialysis, alcohol/ substance abuse, decubitus ulcers, number of co-morbidities, residence in a healthcare institution for ≥72 h in the preceding 180 days, LOS prior to culture (cases) or total LOS (controls), ICU prior to culture (cases) or total LOS (controls), mechanical ventilation, APACHE-II score, prior b-lactam exposure, prior penicillin-class antibiotics, prior fluoroquinolone exposure, prior carbapenems, prior fluoroquinolone ≥5 days, prior b-lactam ≥10 days, prior penicillins ≥8 days and number of prior antibiotic exposures] were included at model entry. The only variable independently associated with CIRE among hospitalized patients was the number of prior antibiotic exposures. Confounding was similarly assessed by putting all variables back into the model that were associated with CIRE in the bivariate analysis at a P value ,0.2 and present in .5% of population. None of the variables changed the final OR for the number of cumulative antibiotic exposures by ≥10%.
A similar strength of association was observed between the number of prior antibiotic exposures and CIRE in the restricted analyses relative to the overall logistic regression analysis ( Table 2 ). The potential of effect modification between the cumulative number of prior antibiotic exposures and clinical covariates was assessed for the overall and restricted multivariate analyses and no departures from multiplicativity (no effect modification) were observed in any analysis.
Discussion
The intent of this study was to define risk factors for Enterobacteriaceae infections with reduced susceptibility to carbapenems. Our results revealed a clear dose-response relationship between Patel et al. Previous evaluations have implicated exposure to specific classes of antibiotics as a risk factor for CIRE infections. 10,11,13,25 -27 In the context of CIRE, one would assume that previous exposure to carbapenems would be the most plausible cause of carbapenem resistance. This, however, was not the case in our study, as we observed a very low frequency of carbapenem usage among cases and both sets of control groups. Given the low frequency of carbapenem usage among cases and controls, one cannot conclude that prior carbapenem use exclusively leads to CIRE. Rather, the data indicate that prior carbapenem use may be one of many cumulative contributory antibiotic insults necessary to augment the risk of CIRE. Interestingly, previous studies only evaluated individual antecedent exposures and did not consider the collective antibiotic exposure history. 10,11,13,25 -27 Our results suggest that future evaluations should consider both individual and cumulative exposures when assessing risk factors for CIRE infections. In addition to considering cumulative antibiotic exposures, future studies should incorporate genetic similarity testing to determine if de novo resistance to carbapenems requires prior carbapenem exposure and if horizontal transmission of carbapenem resistance only requires the disruption of the microbial milieu.
We are not the first to observe the association between the cumulative number of prior antibiotic exposures and infections with reduced antibiotic susceptibility. In previous studies done by our group examining predictors of drug-resistant Pseudomonas aeruginosa respiratory tract infections, the number of antecedent antibiotic exposures was the most important predictor of outcome, more so than the individual antibiotic exposures themselves. 28 -30 Similarly, Hyle et al. 19 determined that the risk of fluoroquinolone-resistant P. aeruginosa infections increased proportionally to the intensity of the antibiotic exposures prior to culture. Collectively, these findings indicate that a patient's cumulative antibiotic exposure history is likely to be more important than any one specific exposure when determining a patient's likelihood of harbouring a resistant pathogen.
Several considerations should be noted when interpreting our findings. A number of different study designs could have been employed to address the aims of this study. We chose to do a case-control study for reasons related to efficiency. With .20 000 Enterobacteriaceae isolates processed by the microbiology laboratory during the study period, it was neither efficient nor necessary to study the entire base population to identify risk factors for CIRE among patients with Enterobacteriaceae infections. Analogously, each CIRE case had, on average, .400 eligible hospitalized controls. While case-control studies can be more efficient, they are much more vulnerable to bias than cohort studies. In our study, we limited the amount of bias by carefully defining our source populations with thoughtful sampling. We used a calliper-based sampling strategy and matched controls to CIRE cases +30 days. Our sampling strategy inherently matches on calendar time. This is noteworthy for hospital-based case-control studies with a long study period because this sampling strategy automatically controls for variables that may change with calendar time (e.g. hospital practices, formulary, prescribing patterns etc.). Future studies should evaluate the importance of these design-related issues in hospital-based case -control studies.
To examine the risk factors of CIRE among hospitalized patients, we restricted our analysis to cases and controls with ≥72 h of hospitalization. We did this because the source population for CIRE cases that occurred within the first 72 h of hospitalization was not readily identifiable or enumerable. The controls in a case -control study should represent the exposure distribution among the source population. For community-onset CIRE cases (,72 h of hospitalization), it was not possible to capture a well-defined or fully enumerable source population that would seek care at AMCH had they been infected with CIRE. Rather than using the hospitalized controls as a secondary base for the community-onset CIRE cases, we chose to restrict the analysis to CIRE cases that were hospital-onset (≥72 h of hospitalization). The advantage of restriction is that it preserves the validity of the estimate(s) without superimposing an unnecessary selection bias.
In conclusion, the cumulative number of prior antibiotic exposures appears to be the most important driver of CIRE infection risk among two different control series. Although patients with CIRE infections had greater disease severity and more co-morbid conditions, the cumulative number of prior antibiotic exposures was the only variable found to be associated with CIRE in all multivariate analyses. While it is likely that a constellation of patient conditions and antibiotic exposures contribute to the development of a CIRE infection, our findings have important implications for empirical therapy selection among patients with a presumed Enterobacteriaceae infection. Our results can also be used to inform future institution-led CIRE risk mitigation strategies. In particular, future CIRE prevention programmes should include efforts to minimize the number of unnecessary antibiotics a patient receives, thus attenuating the risk of a CIRE infection.
